0000000001080693

AUTHOR

Carbone Daniela

0000-0001-5969-7023

showing 3 related works from this author

Nobiletin and xanthohumol sensitize colorectal cancer stem cells to standard chemotherapy

2021

Simple Summary Colorectal cancer stem cells (CR-CSCs) play a pivotal role in the therapy resistance and relapse of CRC patients. Herein we demonstrate that new treatment approaches comprising polymethoxyflavones and prenylflavonoids extracted from Citrus sinensis and Humulus lupulus, respectively, hamper the viability of CR-CSCs as well as synergizing with 5-fluorouracil and oxaliplatin (FOX)-based chemotherapy. Extract fractions containing Nobiletin and Xanthohumol, in combination with chemotherapy, decreased stemness properties of CR-CSCs and restrained the outgrowth of chemoresistant metastatic CR-CSCs. These data pinpoint Nobiletin and Xanthohumol as efficacious anti-cancer compounds in…

0301 basic medicinecancer stem cellCancer ResearchAnti-cancer therapyColorectal cancermedicine.medical_treatmentArticleNobiletin03 medical and health sciences0302 clinical medicineCancer stem cellSettore MED/04 - PATOLOGIA GENERALEMedicineflavonoidClonogenic assayRC254-282FlavonoidsChemotherapybusiness.industryCancer stem cellsWnt signaling pathwayXanthohumolNeoplasms. Tumors. Oncology. Including cancer and carcinogensCell cyclemedicine.diseaseColorectal cancerOxaliplatin030104 developmental biologyOncologyflavonoids; nobiletin; xanthohumol; anti-cancer therapy; cancer stem cells; colorectal cancer; natural biofunctional molecules030220 oncology & carcinogenesisCancer researchNatural biofunctional moleculesStem cellbusinessanti-cancer therapy; cancer stem cells; colorectal cancer; flavonoids; natural biofunctional molecules; nobiletin; xanthohumolmedicine.drug
researchProduct

3-(6-Phenylimidazo [2,1-

2019

A new series of imidazo[2,1-b][1,3,4]thiadiazole derivatives was efficiently synthesized and screened for their in vitro antiproliferative activity on a panel of pancreatic ductal adenocarcinoma (PDAC) cells, including SUIT-2, Capan-1 and Panc-1. Compounds 9c and 9l, showed relevant in vitro antiproliferative activity on all three pre-clinical models with half maximal inhibitory concentration (IC50) ranging from 5.11 to 10.8 µM, while the compounds 9e and 9n were active in at least one cell line. In addition, compound 9c significantly inhibited the migration rate of SUIT-2 and Capan-1 cells in the scratch wound-healing assay. In conclusion, our results will support further studies to increa…

antiproliferative activitymigration assayIndolesimidazo[21-b][134]thiadiazole derivativespancreatic cancerAntineoplastic AgentsAdenocarcinomaindole compoundsArticlePancreatic NeoplasmsresistanceStructure-Activity RelationshipTumor Cells CulturedHumansDrug Screening Assays AntitumorCarcinoma Pancreatic DuctalCell ProliferationMolecules (Basel, Switzerland)
researchProduct

“Open Sesame?”: biomarker status of the human equilibrative nucleoside transporter-1 and molecular mechanisms influencing its expression and activity…

2020

Simple Summary Despite the enormous advance in biomarker discovery, many potential biomarkers of drug activity are unable to satisfy the clinical need due to inadequate sensitivity and specificity. The nucleoside transporter hENT-1 has been studied as a potential biomarker to predict the effect of the widely used anticancer drug gemcitabine in pancreatic cancer. However, several studies showed controversial results regarding the predictive value of hENT-1, prompting new analyses with larger cohorts of patients and standardized methodologies. Improved insights on molecular mechanisms underlying hENT-1 expression and activity should also help in the identification of subsets of patients who a…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyFOLFIRINOXpancreatic cancerSettore BIO/05 - Zoologiaclinical outcomeDUCTAL ADENOCARCINOMAEquilibrative nucleoside transporter 1lcsh:RC254-282Articlehuman equilibrative nucleoside transporter 103 medical and health sciences0302 clinical medicinePancreatic cancerInternal medicinemedicine1112 Oncology and CarcinogenesisScience & Technologydrug resistanceROLESNucleoside analoguebiology1 HENT1business.industryCombination chemotherapyCHEMOTHERAPYlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseSettore CHIM/08 - Chimica FarmaceuticaGemcitabineRegimenLEVELS PREDICT RESPONSE030104 developmental biologyOncology030220 oncology & carcinogenesisCELLSMETASTASISbiology.proteinSURVIVALBiomarker (medicine)ADJUVANT GEMCITABINEbusinessLife Sciences & BiomedicineRESISTANCEmedicine.drug
researchProduct